1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
IDEXX Laboratories's 1-Year ROIIC % for the quarter that ended in Dec. 2023 was -182.48%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for IDEXX Laboratories's 1-Year ROIIC % or its related term are showing as below:
IDXX's 1-Year ROIIC % is ranked worse than 83.17% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: -10.015
vs IDXX: -182.48
IDEXX Laboratories 1-Year ROIIC % Historical Data
The historical data trend for IDEXX Laboratories's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of IDEXX Laboratories's 1-Year ROIIC %
For the Diagnostics & Research subindustry, IDEXX Laboratories's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories's 1-Year ROIIC % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's 1-Year ROIIC % falls into.
IDEXX Laboratories 1-Year ROIIC % Calculation
IDEXX Laboratories's 1-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
IDEXX Laboratories 1-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of IDEXX Laboratories's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
IDEXX Laboratories (IDEXX Laboratories) Business Description
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IDXX has been successfully added to your 